Results 201 to 210 of about 64,427 (282)

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls [PDF]

, 2004
Hagop M. Kantarjian, Susan O’Brien, Jorge E. Cortés, Francis J. Giles, Jianqin Shan, Mary Beth Rios, Stefan Faderl, Srđan Verstovšek, Guillermo Garcia‐Manero, William G. Wierda, Steven M. Kornblau, Alessandra Ferrajoli, Michael J. Keating, Moshe Talpaz   +13 more
openalex   +1 more source

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

The Lancet, 2009
R. DeMatteo, K. Ballman, C. Antonescu, R. Maki, P. Pisters, G. Demetri, M. Blackstein, C. Blanke, M. Mehren, M. Brennan, Shreyaskumar R Patel, M. McCarter, J. Polikoff, B. Tan, K. Owzar   +14 more
semanticscholar   +1 more source

Use of a pH-responsive imatinib mesylate sustained-release hydrogel for the treatment of tendon adhesion by inhibiting PDGFRβ/CLDN1 pathway. [PDF]

Bioact Mater
Pang S, Wu R, Lv W, Zou J, Li Y, Li Y, Zhang P, Ma X, Wang Y, Liu S.   +9 more
europepmc   +1 more source

Periorbital Oedema and epiphora as ocular side effects of imatinib Mesylate (Gleevec) [PDF]

, 2004
Bita Esmaeli, Roxana Diba, Moloud Ahmadi, H.G. Saadati, Misha Faustina, Todd R. Shepler, Moshe Talpaz, R. W. Fraunfelder, Mary Beth Rios, Hagop M. Kantarjian   +9 more
openalex   +1 more source

Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and Prednisone. [PDF]

J Investig Med High Impact Case Rep, 2021
Butterfield JH.
europepmc   +1 more source

Oral Imatinib Mesylate (STI571/Gleevec) Improves the Efficacy of Local Intravascular Vascular Endothelial Growth Factor-C Gene Transfer in Reducing Neointimal Growth in Hypercholesterolemic Rabbits [PDF]

, 2004
Olli Leppänen, Juha Rutanen, Mikko Hiltunen, Tuomas T. Rissanen, Mikko P. Turunen, Tobias Sjöblom, Josef Brüggen, Gudrun Bäckström, Marianne Carlsson, Elisabeth Buchdunger, David Bergqvist, Kari Alitalo, Carl‐Henrik Heldin, Arne Östman, Seppo Ylä‐Herttuala   +14 more
openalex   +1 more source

Safety outcomes of low versus high dose imatinib mesylate in patients with advanced, metastatic, or nonresectable gastrointestinal stromal tumors: A systematic review. [PDF]

Gastrointest Tract
Marucci MA, Lechner DW, Tafuto BA.
europepmc   +1 more source

Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients. [PDF]

Asian Pac J Cancer Prev, 2021
Annuar AA, Ankathil R, Mohd Yunus N, Husin A, Ab Rajab NS, Abdul Aziz AA, Ibrahim MI, Sulong S.   +7 more
europepmc   +1 more source

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase [PDF]

, 2004
Jorge E. Cortés, Susan O’Brien, Alfonso Quintas, Francis J. Giles, Jianquin Shan, Mary Beth Rios, Moshe Talpaz, Hagop M. Kantarjian   +7 more
openalex   +1 more source

Imatinib mesylate induced erythroderma

Indian Journal of Dermatology, Venereology, and Leprology, 2012
Uday Khopkar, Swapnil A Sanghavi, Atul M Dongre   +2 more
openaire   +2 more sources